FMP
Verve Therapeutics, Inc.
VERV
NASDAQ
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
6.22 USD
-0.36 (-5.79%)
About
ceo
Dr. Sekar Kathiresan M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.vervetx.com
exchange
NASDAQ
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and ...
CIK
0001840574
ISIN
US92539P1012
CUSIP
92539P101
Address
500 Technology Square
Phone
617 603 0070
Country
US
Employee
255
IPO Date
Jun 17, 2021
Summary
CIK
0001840574
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92539P101
ISIN
US92539P1012
Country
US
Price
6.22
Beta
1.7
Volume Avg.
1.3M
Market Cap
488.58M
Shares
-
52-Week
6.05-21.42
DCF
1.28
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.99
P/B
-
Website
https://www.vervetx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VERV News
It looks like there's no news available.
